Mineralys Therapeutics (MLYS) Investor Presentation - Slideshow
Mineralys Therapeutics(MLYS)2023-03-29 12:38| --- | --- | --- | |-------|-------|-------| | | | | | | | | Lorundrostat substantially lowered BP compared to placebo by 9.1mmHg at 50mg QD and 10.0 at 100mg QD in uncontrolled and resistant hypertension. Lorundrostat Was Effective At Lowering Blood Pressure In Individuals With Uncontrolled And Resistant Hypertension All measures represent mean placebo-adjusted reductions. No notable effect on cortisol and moderate increase in potassium * Part 1 of Phase 2 Target-HTN Proof of Concept Trial Mineralys Thera ...